Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/18/2022 | $6.00 | Buy | EF Hutton |
4 - G Medical Innovations Holdings Ltd. (0001760764) (Issuer)
3 - G Medical Innovations Holdings Ltd. (0001760764) (Issuer)
EF Hutton initiated coverage of G Medical Innovations with a rating of Buy and set a new price target of $6.00
Rehovot, Israel, Aug. 17, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical Innovations"), an industry innovator in comprehensive remote patient monitoring solutions, today announced that its wholly-owned subsidiary, G Medical Innovations USA, Inc., has entered into an agreement with Resilient Support Services Inc. ("RSS") to expand the health care and remote patient monitoring capabilities to U.S. veterans and military personnel. RSS is a Service-Disabled Veteran-Owned Business that partners with U.S. federal agencies and private sector businesses that are concerned with improving the medical care of veterans and the military community. G Medi
Rehovot, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical Innovations" or the "Company"), a global leader in next-generation mobile health (mHealth) and digital health, today issued the following update to shareholders from President and CEO Dr. Yacov Geva. Dear Fellow Shareholders, We are proud to report that at this halfway point of 2023, G Medical has met several significant milestones and is on track to show revenue growth and gain profitability. Our Company has experienced growth in its monitoring services, and we are getting ready to add revenue with our "At Home Test Kits" business unit as we are no
Rehovot, Israel, May 19, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company, announced today that on May 15, 2023 it received a written notice (the "Notice") from Nasdaq Stock Market LLC, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement.
6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)
6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)
D - G Medical Innovations Holdings Ltd. (0001760764) (Filer)
Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical" or the "Company"), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2022. First Half 2022 Financial Results During the six months period ended June 30, 2022, the Company performed over 100,000 tests which includes four types of diagnostic tests –Rapid Antigen, A/B Flu, PCR and Antibody; in connection with these tests, the Company expects to submit approximately
SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)
SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)
SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)